Author: admin

This article first appeared on GuruFocus.

Novo Nordisk (NVO, Financials) saw renewed attention after Denmark’s patient compensation authority approved payouts to four individuals who experienced vision loss while taking semaglutide-based drugs Wegovy and Ozempic. The patients were awarded a total of 800,000 Danish crowns following a specialist review. One additional claim was rejected.

The authority said the cases were complex because semaglutide has been linked in very rare situations to non-arteritic anterior ischemic optic neuropathy, a condition that can cause permanent vision loss. European regulators added NAION to product labels in June, noting it may occur in up to 1 in 10,000 patients.

Denmark’s compensation authority, which operates independently and is funded by the state, has received 43 claims related to alleged semaglutide-associated vision issues. The rulings do not assign legal liability to Novo Nordisk.

Semaglutide remains central to Novo Nordisk’s diabetes and weight-management portfolio, and demand for both medications remains elevated.

JOHANNESBURG, Nov 21 (Reuters) – A G20 draft leaders’ declaration includes references to “climate change” in defiance of U.S. objections, a source familiar with the matter said on Friday.

Sign up here.

U.S. President Donald Trump recently called climate change a “con job”, and has not sent a delegation to the COP30 climate summit in Brazil.

Our Standards: The Thomson Reuters Trust Principles., opens new tab